Abliva AB Interim Report January – September 2022
Additional regulatory approvals to start the FALCON study with KL1333 ⎮ World Mitochondrial Disease Week raised awareness of mitochondrial diseases
Press releases
Abliva AB Interim Report January – June 2022
SEK 200 million financing secured ⎮ KL1333 study due to start this year ⎮ NV354 is being prepared for clinical studies
Amended number of shares and votes in Abliva AB (publ)
Abliva AB (Nasdaq Stockholm: ABLI) today announces that the number of shares and votes in the Company has increased by 146,547,924, as a result of a preferential rights issue announced by the Board of ...
Last day of trading with BTA in Abliva
Abliva AB has carried out a rights issue where the subscription period ended June 27, 2022. The rights issue has been registered with the Swedish Companies Registration Office (Sw. Bolagsverket) and t ...
Amended number of shares and votes in Abliva AB (publ)
Abliva AB (Nasdaq Stockholm: ABLI) today announces that the number of shares and votes in the Company has increased by 506,744,443, as a result of a directed share issue announced by the Board of Dire ...
Abliva finishes SEK200M financing round with publication of rights issue outcome
Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva”) or the ”Company”) today announces that the new share issue with preferential rights for existing shareholders, announced by the Company on 1 June 2022 (th ...
Abliva publishes prospectus in connection with fully underwritten rights issue and admission to trading of newly issued shares
The Board of Directors in Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has, in connection with the new issues announced on 31 May, 2022, and the conversion of the Company's convertib ...
Abliva decides on a SEK 200 million financing to fund Phase 2/3 study of KL1333 to interim analysis and bring in new global life science and institutional investors
The Board of Directors of Abliva AB (Nasdaq Stockholm: ABLI) (“Abliva” or the “Company”) has approved a directed issue of approximately SEK 150 million to several life science specialist and instituti ...
Abliva AB Interim Report January – March 2022
First quarter summary
Abliva targets SEK 200 million raise to fund the KL1333 Phase 2/3 study to interim analysis
Abliva AB (Nasdaq Stockholm: ABLI) today announced that it intends to raise a financing round of SEK 200 million to provide the company with the capital necessary to run the Phase 2/3 study with KL133 ...
Resolutions from Annual General Meeting in Abliva AB (publ)
Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) today on May 20, 2022 held its Annual General Meeting (“AGM”). A summary of the resolutions follows.
Abliva to issue the Q1 Interim Report by May 31st
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that The Board of Directo ...